Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
Yutaka YamamotoHiroyasu YamashiroAndreas SchneeweissVolkmar MüllerOleg GluzPeter KlareBahriye AktasDank MagdolnaLászló BüdiBéla PikóLászló MangelMasakazu ToiSatoshi MoritaShinji OhnoPublished in: Breast cancer (Tokyo, Japan) (2022)
This international pooled analysis showed the effectiveness of first-line BV + PTX for HER2-negative mBC patients identifying seven independent prognostic factors as real-world evidence. The usefulness of the modified PFI developed in the ATHENA trial in predicting OS among patients receiving BV + PTX was also verified.
Keyphrases
- prognostic factors
- metastatic breast cancer
- end stage renal disease
- lipopolysaccharide induced
- lps induced
- randomized controlled trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- systematic review
- squamous cell carcinoma
- electronic health record
- peritoneal dialysis
- patient reported outcomes
- machine learning
- phase ii
- patient reported